Lamotrigine and the treatment of mania in bipolar disorder.
Anticonvulsants, including valproate and carbamazepine, have established efficacy in the treatment of mania. The anticonvulsant, lamotrigine. has been reported to have antimanic and antidepressant efficacy, and mood-stabilising effects in case reports and preliminary open trials. The efficacy and tolerability of lamotrigine has been compared with olanzapine and lithium in a randomised, prospective, controlled fashion over a period of 4 weeks treatment in a total of 45 hospitalised patients with DSM-IV-defined mania. Significant improvements of a similar magnitude were observed for all treatment groups and lamotrigine was well tolerated. Mechanisms of action proposed to explain the antimanic activity of lamotrigine include inhibition of voltage-sensitive and use-dependent sodium channels, inhibition of glutamate release and calcium channel blockade. Platelet studies have indicated supersensitivity of glutamate receptors and increased intracellular calcium concentrations in patients with mania. Further clinical and mechanistic studies of lamotrigine use in mania are warranted.
Berk
M
M
Department of Psychiatry, University of the Witwatersrand Medical School, Parktown, South Africa. 039berk@chiron.wits.ac.za
D000328:Adult; D000339:Affect / Q000187:drug effects; D018692:Antimanic Agents / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D006801:Humans; D000077213:Lamotrigine; D008094:Lithium / Q000627:therapeutic use; D008297:Male; D016032:Randomized Controlled Trials as Topic; D017470:Receptors, Glutamate / Q000187:drug effects / Q000502:physiology; D015222:Sodium Channels / Q000187:drug effects; D014227:Triazines / Q000009:adverse effects / Q000627:therapeutic use*
D018692:Antimanic Agents; D017470:Receptors, Glutamate; D015222:Sodium Channels; D014227:Triazines; D008094:Lithium; D000077213:Lamotrigine